Moderna's mRNA Flu Vaccine Receives FDA Approval for Older Adults

The FDA has approved Moderna's mFlusiva, the first mRNA-based flu vaccine for individuals aged 50 and above. This regulatory milestone marks a significant advancement in vaccine technology for seasonal influenza prevention, potentially offering a new option for public health. This development could reshape future vaccine strategies.